Risk Factors for Low Lymphocyte Count in Patients With Type 2 Diabetes
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
![](https://webarchive.library.unt.edu/web/20121018192919im_/http://www.clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
The purpose of this study is to identify risk factors for low lymphocyte count among patients with type 2 diabetes who are treated with oral antidiabetic drugs.
Condition |
---|
Diabetes Mellitus, Type 2 |
Study Type: | Observational |
Study Design: | Time Perspective: Prospective |
Official Title: | Identification of Risk Factors for Low Lymphocyte Count in Patients With Type 2 Diabetes: An Analysis of Data From the SAVOR Study |
- To identify risk factors for lymphopenia, defined as an absolute lymphocyte count < 500 cells/μl, or investigator reported lymphopenia, in the SAVOR study population. [ Time Frame: 60 months ] [ Designated as safety issue: Yes ]
- To identify risk factors for absolute lymphocyte count <750 cells/µl or investigator reported lymphopenia. [ Time Frame: 60 months ] [ Designated as safety issue: Yes ]
- To identify risk factors for decreased lymphocyte count (>=30% decrease from baseline. [ Time Frame: 60 months ] [ Designated as safety issue: Yes ]
- To evaluate whether risk factors for low lymphocyte counts or decreasing lymphocyte count differ between saxagliptin users and non-users. [ Time Frame: 60 months ] [ Designated as safety issue: Yes ]
Estimated Enrollment: | 12000 |
Study Start Date: | May 2010 |
Estimated Study Completion Date: | June 2015 |
Estimated Primary Completion Date: | May 2015 (Final data collection date for primary outcome measure) |
Groups/Cohorts |
---|
Patients treated with saxagliptin or placebo
Patients will be treated with saxagliptin or placebo, on top of whatever baseline treatment for diabetes the patient is already receiving.
|
Patients currently or previously on treatment
Patients currently or previously on (within 6 months) treatment with DPP4 inhibitors and/or GLP-1 mimetics are excluded.
|
Detailed Description:
Involving a secondary analysis of data collected prospectively from a defined cohort, for the SAVOR trial.
![](https://webarchive.library.unt.edu/web/20121018192919im_/http://www.clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Ages Eligible for Study: | 40 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Patients enrolled in the Saxagliptin Assessment of Vascular Outcomes Recorded in Diabetes Mellitus study, which is a randomized, placebo-controlled phase 4 study of cardiovascular outcomes). 12,000 patients with type 2 diabetes and either a history of a cardiovascular event or multiple risk factors for vascular disease. Patients will be distributed as follows: at least 30% in North America, approximately 30% in Europe, and the remainder in South America, Asia, Australia, and South Africa.
Inclusion Criteria:
- Enrolled in SAVOR
- Diagnosed with T2DM
- Baseline HbA1c ≥6.5% (based on the last measured and documented laboratory measurement within 6 months)
- Age 40 or older
- High risk for a cardiovascular event
Exclusion Criteria:
- Not enrolled in SAVOR
- Current or previous treatment with DPP4 inhibitors and/or GLP-1 or incretin mimetics.
- Acute vascular event
- Pregnancy
- HIV/AIDS
- Severe autoimmune disease
- Current chronic steroid use
![](https://webarchive.library.unt.edu/web/20121018192919im_/http://www.clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
![](https://webarchive.library.unt.edu/web/20121018192919im_/http://www.clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Additional Information:
No publications provided
Responsible Party: | Bristol-Myers Squibb |
ClinicalTrials.gov Identifier: | NCT01192659 History of Changes |
Other Study ID Numbers: | CV181-102 |
Study First Received: | August 30, 2010 |
Last Updated: | February 17, 2012 |
Health Authority: | United States: Food and Drug Administration Europe:European Agency for the Evaluation of Medicinal Products United Kingdom: Medicines and Healtcare Products Regulatory Agency Czech Republic: State Institute for Drug Control France: Ministry of Health Germany: Ethics Commission Hungary: National Institute of Pharmacy Italy: National Monitoring Centre for Clinical Trials - Ministry of Health Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products Spain: Agencia Espanol de Medicamentos y Productos Sanitarios Sweden: Medical Products Agency Netherlands: The Central Committe on Research Involving Human Subjects (CCMO) Russia: Ministry of Health and Social Development of the Russian Federation Argentina: Ministry of Health Brazil: Ministry of Health Chile: Instituto de Salud Publica de Chile Peru: Instituto Nacioanl de Salud China: State Food and Drug Administration Taiwan: Department of Health Thailand: Food and Drug Administration India: Drugs Controller General of India Israel: Ministry of Health Australia: Department of Health and Aging Goods Administration South Africa: Medicins Control Council Mexico: Federal Commission for Protection Against Health Risks |
Additional relevant MeSH terms:
Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |
ClinicalTrials.gov processed this record on October 17, 2012